Soligenix’s HyBryte Shows Superior Efficacy and Safety Over Valchlor in Cutaneous T-Cell Lymphoma Treatment

Soligenix Inc. announced the publication of positive results from its comparability study evaluating HyBryte versus Valchlor for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy, highlighting favorable efficacy and safety outcomes. After 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to 20% for Valchlor, with greater average improvement and no treatment-related adverse events reported for HyBryte, while Valchlor patients experienced multiple adverse reactions.

These findings support HyBryte’s potential as a well-tolerated therapy for early-stage CTCL, a rare form of non-Hodgkin lymphoma that affects the skin. The study results are particularly significant because they demonstrate not only superior efficacy but also a markedly improved safety profile compared to the existing treatment option. The complete study details are available in the Oncology and Therapy publication, and additional information about the company’s research can be found at https://ibn.fm/SNGX.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company’s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

The implications of these study results extend beyond the immediate patient population, as they demonstrate the potential of photodynamic therapy approaches in oncology treatment. The absence of treatment-related adverse events with HyBryte represents a significant advancement in managing the side effect burden often associated with cancer therapies. This development comes as the company continues to advance its broader pipeline, which includes expansion of synthetic hypericin into psoriasis and development programs for inflammatory diseases and vaccine candidates.

The publication of these results in a peer-reviewed journal adds scientific credibility to the findings and provides clinicians with important data for treatment decision-making. As the company prepares for potential regulatory submissions, these results position HyBryte as a promising therapeutic option that could address both efficacy and tolerability concerns in CTCL management. The full study methodology and detailed results are available through the Oncology and Therapy publication accessible at https://ibn.fm/Eq1BX.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Soligenix’s HyBryte Shows Superior Efficacy and Safety Over Valchlor in Cutaneous T-Cell Lymphoma Treatment.

The post Soligenix’s HyBryte Shows Superior Efficacy and Safety Over Valchlor in Cutaneous T-Cell Lymphoma Treatment appeared first on citybuzz.